New formulations of drugs in epilepsy

James Wheless, Vijay Venkataraman

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The advent of numerous new treatment options in epilepsy therapy over the last decade is enabling a more flexible and individualised approach to patients with seizures. For some patients, these products offer added efficacy, reduction of troublesome side effects associated with standard anticonvulsants, and control over acute seizure exacerbations. This review profiles new formulations of anti-epileptic drugs. Tegretol-XR® (TXR) and Carbatrol® (CBTL), two extended-release preparations of carbamazepine (CBZ), which allow twice daily administration, minimising drug toxicity and improving efficacy. Topiramate sprinkles and lamotrigine chewable dispersible tablets allow easier administration in children. The rectal gel preparation of diazepam (Diastat®) is useful for parents of patients with acute seizure exacerbations. Intravenous valproate (Depacon®) and fosphenytoin (Cerebyx®) provide parenteral treatment of acute seizures, without sedation or significant peripheral venous side effects. All of these new formulations expand treatment options for patients with epilepsy, who will benefit from them. 1999

Original languageEnglish (US)
Pages (from-to)49-60
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume1
Issue number1
DOIs
StatePublished - Jan 1 1999
Externally publishedYes

Fingerprint

Drug Compounding
Epilepsy
Seizures
Carbamazepine
Valproic Acid
Therapeutics
Diazepam
Drug-Related Side Effects and Adverse Reactions
Anticonvulsants
Tablets
Parents
Gels
Pharmaceutical Preparations
fosphenytoin

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

New formulations of drugs in epilepsy. / Wheless, James; Venkataraman, Vijay.

In: Expert Opinion on Pharmacotherapy, Vol. 1, No. 1, 01.01.1999, p. 49-60.

Research output: Contribution to journalArticle

Wheless, James ; Venkataraman, Vijay. / New formulations of drugs in epilepsy. In: Expert Opinion on Pharmacotherapy. 1999 ; Vol. 1, No. 1. pp. 49-60.
@article{267a097d310d4d8d914a074c1441428a,
title = "New formulations of drugs in epilepsy",
abstract = "The advent of numerous new treatment options in epilepsy therapy over the last decade is enabling a more flexible and individualised approach to patients with seizures. For some patients, these products offer added efficacy, reduction of troublesome side effects associated with standard anticonvulsants, and control over acute seizure exacerbations. This review profiles new formulations of anti-epileptic drugs. Tegretol-XR{\circledR} (TXR) and Carbatrol{\circledR} (CBTL), two extended-release preparations of carbamazepine (CBZ), which allow twice daily administration, minimising drug toxicity and improving efficacy. Topiramate sprinkles and lamotrigine chewable dispersible tablets allow easier administration in children. The rectal gel preparation of diazepam (Diastat{\circledR}) is useful for parents of patients with acute seizure exacerbations. Intravenous valproate (Depacon{\circledR}) and fosphenytoin (Cerebyx{\circledR}) provide parenteral treatment of acute seizures, without sedation or significant peripheral venous side effects. All of these new formulations expand treatment options for patients with epilepsy, who will benefit from them. 1999",
author = "James Wheless and Vijay Venkataraman",
year = "1999",
month = "1",
day = "1",
doi = "10.1517/14656566.1.1.49",
language = "English (US)",
volume = "1",
pages = "49--60",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - New formulations of drugs in epilepsy

AU - Wheless, James

AU - Venkataraman, Vijay

PY - 1999/1/1

Y1 - 1999/1/1

N2 - The advent of numerous new treatment options in epilepsy therapy over the last decade is enabling a more flexible and individualised approach to patients with seizures. For some patients, these products offer added efficacy, reduction of troublesome side effects associated with standard anticonvulsants, and control over acute seizure exacerbations. This review profiles new formulations of anti-epileptic drugs. Tegretol-XR® (TXR) and Carbatrol® (CBTL), two extended-release preparations of carbamazepine (CBZ), which allow twice daily administration, minimising drug toxicity and improving efficacy. Topiramate sprinkles and lamotrigine chewable dispersible tablets allow easier administration in children. The rectal gel preparation of diazepam (Diastat®) is useful for parents of patients with acute seizure exacerbations. Intravenous valproate (Depacon®) and fosphenytoin (Cerebyx®) provide parenteral treatment of acute seizures, without sedation or significant peripheral venous side effects. All of these new formulations expand treatment options for patients with epilepsy, who will benefit from them. 1999

AB - The advent of numerous new treatment options in epilepsy therapy over the last decade is enabling a more flexible and individualised approach to patients with seizures. For some patients, these products offer added efficacy, reduction of troublesome side effects associated with standard anticonvulsants, and control over acute seizure exacerbations. This review profiles new formulations of anti-epileptic drugs. Tegretol-XR® (TXR) and Carbatrol® (CBTL), two extended-release preparations of carbamazepine (CBZ), which allow twice daily administration, minimising drug toxicity and improving efficacy. Topiramate sprinkles and lamotrigine chewable dispersible tablets allow easier administration in children. The rectal gel preparation of diazepam (Diastat®) is useful for parents of patients with acute seizure exacerbations. Intravenous valproate (Depacon®) and fosphenytoin (Cerebyx®) provide parenteral treatment of acute seizures, without sedation or significant peripheral venous side effects. All of these new formulations expand treatment options for patients with epilepsy, who will benefit from them. 1999

UR - http://www.scopus.com/inward/record.url?scp=0033224355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033224355&partnerID=8YFLogxK

U2 - 10.1517/14656566.1.1.49

DO - 10.1517/14656566.1.1.49

M3 - Article

C2 - 11249564

AN - SCOPUS:0033224355

VL - 1

SP - 49

EP - 60

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 1

ER -